Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emanuela Marchesini
Observed names:
E. MARCHESINI,
E. Marchesini,
Marchesini, Emanuela
Institution:
Azienda Ospedaliera di Perugia
Observed institutions:
Queen Mary University of London,
University of Perugia,
Royal London Hospital,
University Hospital Southampton NHS Foundation Trust,
Azienda Ospedaliera di Perugia,
World Federation of Hemophilia,
Bayer (Germany)
show all 7
ORCID:
0000-0001-8584-9908
Observed ORCID:
0000-0001-8584-9908
OpenAlex ID:
A5011284190
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review
2010
·
A. IORIO
, S. HALIMEH
, et al.
·
Journal of Thrombosis and Haemostasis
·
279
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
2011
·
Alfonso Iorio
, Emanuela Marchesini
, et al.
·
Cochrane Database of Systematic Reviews
·
195
PDF
Recent Advances in the Treatment of Hemophilia: A Review
2021
·
Emanuela Marchesini
, Massimo Morfini
, et al.
·
Biologics
·
85
PDF
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
2020
·
Giancarlo Castaman
, Cristina Santoro
, et al.
·
Blood transfusion
·
59
PDF
Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study
2018
·
Maria Cristina Vedovati
, Michela Giustozzi
, et al.
·
International Journal of Cardiology
·
50
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII
2015
·
Davide Matino
, Marco Gargaro
, et al.
·
Journal of Clinical Investigation
·
49
PDF
The good use of plasma. A critical analysis of five international guidelines.
2008
·
Alfonso Iorio
, Michela Basileo
, et al.
·
PubMed
·
36
Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study
2014
·
M. Morfini
, E. Marchesini
, et al.
·
Haemophilia
·
24
Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus
2010
·
Alfonso Iorio
, Emanuela Marchesini
, et al.
·
Cochrane Database of Systematic Reviews
·
24
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
2022
·
Annarita Tagliaferri
, Angelo Claudio Molinari
, et al.
·
Haemophilia
·
18
PDF
Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population
2017
·
E. Marchesini
, E. Oliovecchio
, et al.
·
Haemophilia
·
17
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding
2021
·
Melina Verso
, Michela Giustozzi
, et al.
·
Thrombosis Research
·
14
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life
2016
·
Michela Giustozzi
, Maria Cristina Vedovati
, et al.
·
European Journal of Internal Medicine
·
14
Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus
2009
·
Lise Lotte Gluud
, Emanuela Marchesini
, et al.
·
The American Journal of Gastroenterology
·
14
Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase.
2008
·
Alfonso Iorio
, Michela Basileo
, et al.
·
PubMed
·
14
Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.
2018
·
Piercarla Schinco
, Giancarlo Castaman
, et al.
·
Blood transfusion
·
12
PDF
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls
2018
·
Pier Mannuccio Mannucci
, Alessandro Nobili
, et al.
·
Haemophilia
·
9
Addressing the impact of SARS‐CoV‐2 infection in persons with congenital bleeding disorders: The Italian MECCOVID‐19 study
2021
·
Antonella Coluccia
, Emanuela Marchesini
, et al.
·
Haemophilia
·
6
The availability of new drugs for hemophilia treatment
2020
·
Massimo Morfini
, Emanuela Marchesini
·
Expert Review of Clinical Pharmacology
·
5
Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies
2015
·
Matteo Nicola Dario Di Minno
, Emanuela Marchesini
, et al.
·
Blood
·
5
Randomised, Open, Prospective, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor Viia (novoseven) in Acute Intracerebral Haemorrhage in Patients Treated With Oral Anticoagulant or Antiplatelet Agents
2007
·
A. Iorio
, E. Marchesini
, et al.
·
Journal of Thrombosis and Haemostasis
·
4
Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long‐term prophylaxis: An expert opinion paper from an Italian panel
2022
·
Giancarlo Castaman
, Alessandra Borchiellini
, et al.
·
European Journal Of Haematology
·
3
PDF
Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors
2011
·
Emanuela Marchesini
, Domenico Prisco
, et al.
·
European Oncology & Haematology
·
3
Launch of a National Registry for Congenital Hematological Disorders in Palestine: the Haemo-PAL Initiative
2026
·
Fabio Candura
, Emanuela Marchesini
, et al.
·
Bleeding Thrombosis and Vascular Biology
·
1
Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia
2021
·
Silvia Riva
, Emanuela Marchesini
, et al.
·
Haemophilia
·
1
Show more works
View as search
Works count:
40
Citation count:
943
H-index:
14
I10-index:
16
Year
Topic
Type